EMA issues second negative recommendation for plitidepsin combination

The European Medicines Agency (EMA) has issued a second negative recommendation for plitidepsin (AplidinĀ®) in combination with dexamethasone for the treatment of relapsed and refractory myeloma. The application to authorise this treatment combination was re-examined by the EMA after receiving an initial negative recommendation in December 2017. This decision was based upon data from the…

Details